PDT Partners’s Bolt Biotherapeutics BOLT Stock Holding History

PDT Partners’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-611	Closed	-$33K	–	967
2022 Q1	$33K	Buy	+611	New	+$41.1K	﹤0.01%	908

Other funds holding BOLT

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

PDT Partners's BOLT Position: Q2 2022 in Review

PDT Partners sold out of Bolt Biotherapeutics (BOLT) in Q2 2022, closing a stake of 611 shares — an estimated $33K sold.

PDT Partners first reported a position in BOLT in Q1 2022 and held it in 1 quarter. The position peaked at $33K in Q1 2022. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2022.

PDT Partners reported no remaining Bolt Biotherapeutics position as of Q2 2022 after selling out during the quarter.
PDT Partners sold 611 Bolt Biotherapeutics shares in Q2 2022, an estimated $33K.
PDT Partners first reported a position in Bolt Biotherapeutics in Q1 2022 and held it in 1 quarter.
PDT Partners's Bolt Biotherapeutics position peaked at $33K in Q1 2022.
61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.